VK2735 vs Retatrutide
VK2735 vs Retatrutide: dual vs triple agonist, the oral option vs the strongest trial numbers.
The verdict
Two of the most-watched next-generation weight-loss compounds, both still in trials. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) with the biggest weight-loss numbers in the class. VK2735 is a dual agonist (GLP-1 + GIP), and its real draw is the oral version rather than raw effect size. Neither is approved. If the headline is maximum trial weight loss, Retatrutide leads. If it is a needle-free future, VK2735 is the one to watch. For now both are investigational and source quality is the real risk.
VK2735 is an experimental weight-loss drug from Viking Therapeutics. It works on two gut-hormone receptors (GLP-1 and GIP) to cut appetite, the same combo as Tirzepatide. The notable part is the pill version: in early trials a once-daily tablet got close to the results of the injection. It is still in testing and not approved.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick VK2735 if people following the oral-glp-1 race who want a needle-free option or users tracking next-generation weight-loss compounds before approval.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between VK2735 and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Common questions
- Can you stack VK2735 with Retatrutide?
- Neither entry lists the other as a stack partner. Each full entry has its own stacking notes.
- What's the dose difference between VK2735 and Retatrutide?
- VK2735: No approved human dosing. In Phase 2, the injectable (the VENTURE program) was titrated weekly and an oral Phase 2 ran once-daily, both over 13 weeks. Outside a clinical trial there is no established protocol, and access is trial-only.
- Retatrutide: Start 2mg sub-q weekly. Titrate by 2mg every 4 weeks based on tolerance. Trials went up to 12mg; most users plateau benefit at 8-12mg.
- Is VK2735 or Retatrutide FDA approved?
- VK2735: Investigational. The injectable is in Phase 3 (begun 2025); the oral form is expected to enter Phase 3 around late 2026. Pivotal readouts are not expected before 2027. Not approved.
- Retatrutide: Investigational. In Phase 3 trials with Eli Lilly. Not yet approved.
- What are the side effects of VK2735 vs Retatrutide?
- VK2735: Nausea (most common, usually mild to moderate); Vomiting; Diarrhea or constipation.
- Retatrutide: Nausea (especially first 2 weeks of each titration step); Vomiting; Constipation or diarrhea.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.